Antibodies: Friends, Foes, or Both? Lessons From COVID-19 for the Rheumatologist.
J Clin Rheumatol
; 28(1): e263-e269, 2022 Jan 01.
Article
in English
| MEDLINE | ID: covidwho-1180689
ABSTRACT
ABSTRACT Antibodies are a fundamental tool to fight infections but are intrinsically built as a double-edged sword. One side recognizes the microbial antigen, and the other gives a call to arms to fight infection by recruiting immune cells and triggering inflammation. A balanced immune response must combine a potent neutralizing antibody and a swift disposal of the invading agent by innate immune cells with the least tissue damage possible. The longer the immune system takes to control the infection, the higher the possibility for a self-sustaining inflammatory process with potentially fatal consequences for the host. In addition to quantity, the quality of antibodies also matters, because posttranslational modifications altering the N-glycan composition in Fc fractions may help tilt the balance to the effector side, by modifying their affinity for Fc receptors in immune cells. The COVID-19 pandemic has provided a wealth of data bolstering our understanding of the rules governing the production of protective and nonprotective antibodies. Also, it has broadened our understanding of the role of viruses in triggering autoimmunity and inflammation, and widened our knowledge of the different mechanisms that can be activated by viral infection and lead to autoantibody production, inflammation, and progressive tissue damage. In addition, the COVID-19 infection has contributed a great deal to our comprehension of the role of antibodies in the causation of cytokine storms and systemic inflammatory response syndrome, also seen in patients with systemic autoimmune diseases.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rheumatologists
/
COVID-19
Limits:
Humans
Language:
English
Journal:
J Clin Rheumatol
Journal subject:
Physiology
/
Orthopedics
/
Rheumatology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS